Clinical Trial: NCT03769103
Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | British Columbia Cancer Agency |
| Information Provided By: | British Columbia Cancer Agency |
| Last Update Posted: | 2024-10-31 |
Study Overview
Brief Summary
This open-label, multicenter, randomized phase II study will evaluate the usage of osimertinib alone for brain metastases compared to SRS and osimertinib in patients with newly diagnosed, treatment naiive EGFR positive lung cancer.
Official Title
Open Label, Multicenter, Phase II Study of Patients With Treatment Naïve Metastatic Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases Randomized to Stereotactic Radiosurgery (SRS) and Osimertinib or Osimertinib Alone
Conditions
Lung Cancer Non-small Cell Stage IV, Brain Metastases
Intervention / Treatment
- Drug: Osimertinib
- Radiation: Stereotactic radiotherapy
Other Study ID Numbers
- LUOSICNS
Start Date (Actual)
2019-03-19
Primary Completion Date (Estimated)
2025-04
Study Completion Date (Estimated)
2025-04
Enrollment (Actual)
40
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | British Columbia Cancer Agency |
| Information Provided By: | British Columbia Cancer Agency |
| Last Update Posted: | 2024-10-31 |
Study Overview
Brief Summary
This open-label, multicenter, randomized phase II study will evaluate the usage of osimertinib alone for brain metastases compared to SRS and osimertinib in patients with newly diagnosed, treatment naiive EGFR positive lung cancer.
Official Title
Open Label, Multicenter, Phase II Study of Patients With Treatment Naïve Metastatic Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases Randomized to Stereotactic Radiosurgery (SRS) and Osimertinib or Osimertinib Alone
Conditions
Lung Cancer Non-small Cell Stage IV, Brain Metastases
Intervention / Treatment
- Drug: Osimertinib
- Radiation: Stereotactic radiotherapy
Other Study ID Numbers
- LUOSICNS
Start Date (Actual)
2019-03-19
Primary Completion Date (Estimated)
2025-04
Study Completion Date (Estimated)
2025-04
Enrollment (Actual)
40
Study Type
Interventional
Phase
Phase 2